Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 3
Submit an article Journal homepage
19
Views
5
CrossRef citations to date
0
Altmetric
Review

Measuring health-related quality of life in women on hormone replacement therapy

Harri Sintonen University of Helsinki, Department of Public Health, Helsinki, Finland
,
Stiina Johansson University of Helsinki, Department of Public Health, Helsinki, Finland
,
Arto Ohinmaa University of Helsinki, Department of Public Health, Helsinki, Finland
,
Marjo Apajasalo University of Helsinki, Department of Public Health, Helsinki, Finland
,
Petri Kainulainen University of Helsinki, Department of Public Health, Helsinki, Finland
&
Jorma Heikkinen University of Helsinki, Department of Public Health, Helsinki, Finland
Pages 351-361 | Published online: 09 Jan 2014

References

  • Zichella L. Clinical management of the menopausal woman. Int. J Fertil Menopausal. Stud. 38(Supp.1), 15–22 (1993).
  • Oldenhave A, Netelenbos C. Pathogenesis of climacteric complaints: ready for the change? Lancet 343(8898), 649–653 (1994).
  • Compston JE. Osteoporosis. Clin. Endocrinol 33(5), 653–682 (1990).
  • Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CM4J167\(Suppl. 10), S1—S34 (2002).
  • Mattsson LA, Samsioe G. Estrogen— progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen. Acta Obstet. Gynecol Land. Suppl 130,53–58 (1985).
  • Persson I, Adami HO, Bergkvist L et al Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Brit. Med 298 (6667), 147–151 (1989).
  • Mattsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen—progestogen regimen for climacteric complaints. 11/13turitas 4(2), 95–102 (1982).
  • MacKeigan LD, Pathak DS. Overview of health-related quality-of-life measures. Am J. Hosp. Pharm. 49,2236–2245 (1992).
  • World Health Organization. Constitution of the World Health Organization, Annex 1. In: The First Ten Years of the World Health Organization. World Health Organization, Geneva, Switzerland (1958).
  • Schipper H, Clinch JJ, Olweny CLM. Quality of Life Studies: Definitions and Conceptual Issues. In: Quality of Life and Pharmacoeconomin 5. in Clinical Tiials Spilker B (Ed.). Lippincott-Raven Publishers, Philadelphia, PA, USA 11–23 (1996).
  • Olschewski M, Schulgen G, Schumacher M, Altman DG. Quality of life assessment in clinical cancer research. Brit. J Cancer 70,1–5 (1994).
  • Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann. Intern. Med 118,622–629 (1993).
  • Rabin R, de Charro E EQ-5D: a measure of health status from the EuroQol Group. Ann. Med 33(5), 337–343 (2001).
  • Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Sac Sc] Med A. 15(3 Pt 1), 221–229 (1981).
  • Ware JE Jr, Sherboume CD. The MOS 36- item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6), 473–483 (1992).
  • Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19(8), 787–805 (1981).
  • Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUT) system for assessing health-related quality of life in clinical studies. Ann. Med 33(5), 375–384 (2001).
  • Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann. Med. 33(5), 328–336 (2001).
  • Guyatt GH, Jaeschke RJ. Reassessing quality-of-life instruments in the evaluation of new drugs. PharmacoEconomics. 12(6), 621–626 (1997).
  • Kaplan RM, Anderson JR A general health policy model: update and applications. Health Serv. Res. 23,203–235 (1988).
  • Martinez-Martin P Health-related quality of life in Parkinson's disease: outcomes of the therapeutic interventions. Expert Rev Pharmacoeconomics Outcomes Res. 1,99–108 (2001).
  • Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. jAm. Med Assoc. 272, 619–626 (1994).
  • Jolicoeur LM, Jones-Grizzle AJ, Boyle JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hasp. Pharm. 49,1741–1747 (1992).
  • Brooks R, with the EuroQol Group. EuroQol: the current state of play. Health Policy37, 53–72 (1996).
  • Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 8(3), 209–224 (1999).
  • Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin. Epidemiol 51(11), 1115–1128 (1998).
  • Hunter M. The Womenis Health Questionnaire: a measure of mid-aged womenis perceptions of their emotional and physical health. Psychology I-kalth7, 45–54 (1992).
  • •Provides additional details on the Women's Health Questionnaire, which is the only existing health-related quality of life questionnaire measure for postmenopausal women.
  • Ryan N, Rosner A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysteieutornized, postmenopausal women. Clin. firer 23(7), 1099–1115 (2001).
  • Voss S, Quail D, Dawson A etal A randomised, double-blind trial comparing raloxifene HC1 and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 109(8), 874–885 (2002).
  • Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermg estradiol therapy: a double-blind placebo-controlled study. Am J Ulster. Gynecol 168(3 Pt 1), 824–830 (1993).
  • Limouzin-Lamothe MA, Mairon N, Joyce CR, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am j Obstet. Gynecol 170(2), 618–624 (1994).
  • Karlberg J, Mattsson LA, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Ulster. Gynecol Land. 74(5), 367–372 (1995).
  • Strickler R, Stovall DW, Merritt D, Shen W Wong M, Silfen SL. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet. Gynecol 96(3), 359–365 (2000).
  • Genazzani AR, Nicolucci A, Campagnoli C et al Assessment of the QOL in Italian menopausal women: comparison between HRT users and nonusers. Maturitas 42(4), 267–280 (2002).
  • Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 14(3), 225–236 (1992).
  • Fitzpatrick LA, Pace C, Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J. Womens Health Gend. Based Med. 9(4), 381–387 (2000).
  • Ulrich LG, Barlow DH, Sturdee DW eta]. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. Int. J. Gynaecol Obstet. 59\(Suppl. 1), S11—S17 (1997).
  • Huber J, Palacios S, Berglund L etal Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 109(8), 886–893 (2002).
  • Wildund I, Holst J, Karlberg J et al A new methodological approach to the evaluation of quality of life in postmenopausal women. 11/Lituritas 14(3), 211–224 (1992).
  • Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. Brit. Med. 307(6908), 836–840 (1993).
  • Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Brit. J. Obstet. Gynaecol 104(10), 1191–1195 (1997).
  • •A willingness-to-pay study of hormone replacement therapy in postmenopausal women. In addition, it introduces and discusses the time tradeoff and rating scale methods in measuring the impact of hormone replacement therapy on health-related quality of life.
  • Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 4(4), 314–319 (2001).
  • Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/ Progestin Replacement Study (HERS) trial. 161/1//A 287(5), 591–597 (2002).
  • Heikkinen JE, Vaheri RT, Ahomaki SM, Kainulainen PM, Viitanen AT, Timonen UM. Optimizing continuous—combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am. J. Obstet. Gynecol 182(3), 560–567 (2000).
  • Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen—progestine regimens. Osteoporos. Int. 11(11), 929–937 (2000).
  • Stavem K. Reliability, validity and responsiveness of two multi attribute utility measures in patients with chronic obstructive pulmonary disease. Quality of Life Research 8 (1-2), 45–54 (1999) .
  • Rissanen P, Sogaard J, Sintonen H. Do QOL instruments agree? A comparison of the 15D and NHP in hip and knee replacements. Int. J. Technol Assess Healthcare 16(2), 696–705 (2000).
  • •Compares the 15D and Nottingham Health Profile measures using statistical models.
  • Malmivaara A, Hakkinen U, Aro T et al The treatment of acute low back pain—bed rest, exercises, or ordinary activity? N Engl. J. Med. 332(6), 351–355 (1995).
  • Kauppinen R, Sintonen H, Tuldainen H. One- year economic evaluation of intensive versus conventional patient education and supervision for self-management of new asthmatic patients. Respir Med. 92(2), 300–307 (1998).
  • Wiklund I, Karlberg J. Evaluation of quality of life in clinical trials. Selecting quality-of-life measures. Controlled Clinical Trials. 12(Suppl), 204–216 (1991).
  • Koivukangas P, Ohinmaa A, Koivukangas J. Nottingham Health Profilen (NHP) suomalainen versio. STAKES, Report No. 187, Helsinki, Finland 1–87 (1995).
  • Amen S, Hakkinen U, Klaukka T, Klavus J, Lehtonen R, Aro S. Health and the use of health services in Finland. Main findings of the Finnish Healthcare Survey 1995/96 and changes from 1987. Official Statistics of Finland, Helsinki, Finland (1998).
  • Kauppinen R, Sintonen H, Vilkka V, Pekurinen M, Tukiainen H. Quality-of-life measures and clinical parameters in asthmatics during three year follow-up. Monaldi. Arch. Chest Dis. 53(4), 400–404 (1998).
  • Hyland ME. The validity of health assessments: resolving some recent differences. J. Clin. Epidemiology 46, 1019–1023 (1993).
  • Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. Oxford University Press, Oxford (UK), NY (USA), Tokyo (Japan) (1989).
  • Juniper EF, Guyatt GH, Jaeschke R How to Develop and Validate a New Health-Related Quality of Life Instrument. In: Quality of Life and Phalmacoeconomics in Clinical Trials Spilker B (Ed.). Lippincott-Raven Publishers, PA, USA 49–56 (1996).
  • •Guide to key issues involved in the development and validation of a health-related quality of life measure.
  • Kirshner B, Guyatt G. A methodological framework for assessing health indices. J. Chronic Dis. 38(1), 27–36 (1985).
  • Patrick DL, Erickson P. Assessing health- related quality of life for clinical decision-making. In: Quality of life Assessment in Clinical Trials. Spilker B (Ed.). Raven Press, NY, USA 11–63 (1993).
  • Sintonen H. Outcome measurement in acid-related disease. PhalmacoEconomics 5 (Suppl. 3), 17–26 (1994).
  • McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. Oxford University Press, NY, USA (1987).

Websites

  • http://chpe.buseco.monash.edu.au (Accessed April 2003). Publications: working papers 41 and 42. \
  • •Introduces and discusses the properties of the 15D measure. 15D is compared with the Nottingham Health Profile, SF-20 and EuroQoL by using several data sets and methods.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.